Skip to main content
Erschienen in: Rheumatology International 7/2008

01.05.2008 | Case Report

Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis

verfasst von: Paolo Airo’, Mirko Scarsi, Mara Rossi, Michele Mondini

Erschienen in: Rheumatology International | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

The coexistence of systemic sclerosis (SSc) and multiple sclerosis (MS) in the same patient has been described in few cases. We refer here a further case of association between these diseases, which highlight the difficulty of treating such patients. A 57-year-old male with relapsing-remitting MS since 20 years, shortly after having received high-dose corticosteroids for a relapse of MS, suddenly developed SSc, with onset of Raynaud phenomenon simultaneous to that of scleroderma skin involvement, new appearance of accelerated arterial hypertension, and rapidly progressive oliguric renal failure, indicative of scleroderma renal crisis, that was controlled with ramipril, irbesartan and amlodipin. A further disabling relapse of MS was treated with interferon-beta, but 19 months later he developed multiple severe digital necrotic ulcers, that resolved with interferon discontinuation and therapy with iloprost. This case report shows that some form of treatment useful for MS might enhance the manifestations of SSc.
Literatur
1.
Zurück zum Zitat Sakkas LI, Xu B, Artlett CA, Lu S, Jimenez SA, Platsoucas CD (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168:3649–3659PubMed Sakkas LI, Xu B, Artlett CA, Lu S, Jimenez SA, Platsoucas CD (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168:3649–3659PubMed
2.
Zurück zum Zitat Trostle DC, Helfrich D, Medsger TA Jr (1986) Systemic sclerosis (scleroderma) and multiple sclerosis. Arthritis Rheum 29:124–127PubMedCrossRef Trostle DC, Helfrich D, Medsger TA Jr (1986) Systemic sclerosis (scleroderma) and multiple sclerosis. Arthritis Rheum 29:124–127PubMedCrossRef
3.
Zurück zum Zitat Igarashi A, Imakado S, Ishibashi Y, Takehara K (1989) Systemic sclerosis associated with multiple sclerosis. Arch Dermatol 125:1145PubMedCrossRef Igarashi A, Imakado S, Ishibashi Y, Takehara K (1989) Systemic sclerosis associated with multiple sclerosis. Arch Dermatol 125:1145PubMedCrossRef
4.
Zurück zum Zitat Jawad SH, Askari A, Ward AB (1997) Case history of a patient with multiple sclerosis and scleroderma. Br J Rheumatol 36:502–503PubMedCrossRef Jawad SH, Askari A, Ward AB (1997) Case history of a patient with multiple sclerosis and scleroderma. Br J Rheumatol 36:502–503PubMedCrossRef
5.
Zurück zum Zitat Spadaro A, Sensi F, Barrella M, Francia A (1999) Systemic sclerosis and multiple sclerosis. J Neurol 246:497–499PubMedCrossRef Spadaro A, Sensi F, Barrella M, Francia A (1999) Systemic sclerosis and multiple sclerosis. J Neurol 246:497–499PubMedCrossRef
6.
Zurück zum Zitat Chroni E, Paschalis C, Stergiou T, Vlahanastasi C, Andonopoulos AP (2002) Multiple sclerosis in the course of systemic sclerosis. Ann Rheum Dis 61:188–190PubMedCrossRef Chroni E, Paschalis C, Stergiou T, Vlahanastasi C, Andonopoulos AP (2002) Multiple sclerosis in the course of systemic sclerosis. Ann Rheum Dis 61:188–190PubMedCrossRef
7.
Zurück zum Zitat Gorodkin R, Leahy B, Neary D, Herrick AL (2004) Coexistence of systemic sclerosis and multiple sclerosis. J Neurol 251:1524–1525PubMedCrossRef Gorodkin R, Leahy B, Neary D, Herrick AL (2004) Coexistence of systemic sclerosis and multiple sclerosis. J Neurol 251:1524–1525PubMedCrossRef
8.
Zurück zum Zitat Pelidou SH, Tsifetaki N, Giannopoulos S, Deretzi G, Voulgari P, Kyritsis A (2007) Multiple sclerosis associated with systemic sclerosis. Rheumatol Int 27:771–773PubMedCrossRef Pelidou SH, Tsifetaki N, Giannopoulos S, Deretzi G, Voulgari P, Kyritsis A (2007) Multiple sclerosis associated with systemic sclerosis. Rheumatol Int 27:771–773PubMedCrossRef
9.
Zurück zum Zitat Do HT, Baars W, Borns K, Windhagen A, Schwinzer R (2006) The 77C > G mutation in the human CD45 (PTPRC) gene leads to increased intensity of TCR signalling in T cell. J Immunol 176:931–938PubMed Do HT, Baars W, Borns K, Windhagen A, Schwinzer R (2006) The 77C > G mutation in the human CD45 (PTPRC) gene leads to increased intensity of TCR signalling in T cell. J Immunol 176:931–938PubMed
10.
Zurück zum Zitat Schwinzer R, Witte T, Hundrieser J, Ehlers S, Momot T, Hunzelmann N, Krieg T, Schmidt RE, Wonigeit K (2003) Enhanced frequency of a PTPRC (CD45) exon A mutation (77C– > G) in systemic sclerosis. Genes Immun 4:168–169PubMedCrossRef Schwinzer R, Witte T, Hundrieser J, Ehlers S, Momot T, Hunzelmann N, Krieg T, Schmidt RE, Wonigeit K (2003) Enhanced frequency of a PTPRC (CD45) exon A mutation (77C– > G) in systemic sclerosis. Genes Immun 4:168–169PubMedCrossRef
11.
Zurück zum Zitat Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231PubMedCrossRef Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231PubMedCrossRef
12.
Zurück zum Zitat Mondini M, Vidali M, De Andrea M, Azzimonti B, Airo’ P, D’ambrosio R, Riboldi P, Meroni PL, Albano E, Schoenfeld Y, Gariglio M, Landolfo S (2006) A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis Rheum 54:3939–3944PubMedCrossRef Mondini M, Vidali M, De Andrea M, Azzimonti B, Airo’ P, D’ambrosio R, Riboldi P, Meroni PL, Albano E, Schoenfeld Y, Gariglio M, Landolfo S (2006) A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. Arthritis Rheum 54:3939–3944PubMedCrossRef
13.
Zurück zum Zitat Airo’ P, Rossi M, Scarsi M, Danieli E, Grottolo A, Zambruni A (2007) Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group. Clin Exp Rheumatol (in press) Airo’ P, Rossi M, Scarsi M, Danieli E, Grottolo A, Zambruni A (2007) Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group. Clin Exp Rheumatol (in press)
14.
Zurück zum Zitat Theodoridou A, Settas L (2006) Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 77:290–295PubMed Theodoridou A, Settas L (2006) Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 77:290–295PubMed
15.
Zurück zum Zitat DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Clements PJ (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46:2983–2989PubMedCrossRef DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Clements PJ (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46:2983–2989PubMedCrossRef
16.
17.
Zurück zum Zitat Linden D (1998) Severe Raynaud’s phenomenon associated with interferon-beta treatment for multiple sclerosis. Lancet 352:878–879PubMedCrossRef Linden D (1998) Severe Raynaud’s phenomenon associated with interferon-beta treatment for multiple sclerosis. Lancet 352:878–879PubMedCrossRef
18.
Zurück zum Zitat DeBroucker T, Lhote F (2000) Severe Raynaud’s phenomenon associated with interferon-beta 1a and fluoxetine. Ann Med Interne (Paris) 15:424–425 DeBroucker T, Lhote F (2000) Severe Raynaud’s phenomenon associated with interferon-beta 1a and fluoxetine. Ann Med Interne (Paris) 15:424–425
19.
Zurück zum Zitat Cruz BA, De Queiroz E, Vilela Nunes S, Cruz Filho A, Campos GB, Lentz deCarvalho Monteiro E, Crivellari H (2000) Fênomeno de Raynaud grave associado a terapia com interferon-beta para esclerose múltipla. Arq Neuropsiquiatr 58:556–559PubMed Cruz BA, De Queiroz E, Vilela Nunes S, Cruz Filho A, Campos GB, Lentz deCarvalho Monteiro E, Crivellari H (2000) Fênomeno de Raynaud grave associado a terapia com interferon-beta para esclerose múltipla. Arq Neuropsiquiatr 58:556–559PubMed
20.
Zurück zum Zitat Schapira D, Nahir AM, Hadad N (2002) Interferon-induced Raynaud’s syndrome. Semin Arthritis Rheum 32:57–62CrossRef Schapira D, Nahir AM, Hadad N (2002) Interferon-induced Raynaud’s syndrome. Semin Arthritis Rheum 32:57–62CrossRef
21.
Zurück zum Zitat Beretta L, Caronni M, Vanoli M, Scorza R (2002) Systemic sclerosis after interferon alfa therapy for myeloproliferative disorders. Br J Dermatol 147:385–386PubMedCrossRef Beretta L, Caronni M, Vanoli M, Scorza R (2002) Systemic sclerosis after interferon alfa therapy for myeloproliferative disorders. Br J Dermatol 147:385–386PubMedCrossRef
22.
Zurück zum Zitat Solans R, Bosch JA, Esteban I, Vilardell M (2004) Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 22:625–628PubMed Solans R, Bosch JA, Esteban I, Vilardell M (2004) Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 22:625–628PubMed
23.
Zurück zum Zitat Tahara H, Kojima A, Hirokawa T, Oyama T, Naganuma A, Maruta S, Okada K, Ban S, Yoshida K, Takagi H, Mori M (2007) Systemic sclerosis after interferon alphacon-1 therapy for Hepatitis C. Intern Med 46:473–476PubMedCrossRef Tahara H, Kojima A, Hirokawa T, Oyama T, Naganuma A, Maruta S, Okada K, Ban S, Yoshida K, Takagi H, Mori M (2007) Systemic sclerosis after interferon alphacon-1 therapy for Hepatitis C. Intern Med 46:473–476PubMedCrossRef
24.
Zurück zum Zitat Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, Pompon L, Shi-Wen X (1999) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arhritis Rheum 42:299–305CrossRef Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, Pompon L, Shi-Wen X (1999) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arhritis Rheum 42:299–305CrossRef
25.
Zurück zum Zitat Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, Jin L, Arnett FC Jr (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology 45:694–702PubMedCrossRef Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, Jin L, Arnett FC Jr (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology 45:694–702PubMedCrossRef
Metadaten
Titel
Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis
verfasst von
Paolo Airo’
Mirko Scarsi
Mara Rossi
Michele Mondini
Publikationsdatum
01.05.2008
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 7/2008
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-007-0507-2

Weitere Artikel der Ausgabe 7/2008

Rheumatology International 7/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.